Ruxolitinib, Cladribine, VenetoclaxPhase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic Leukemia

Sponsor:

M.D. Anderson Cancer Center

Code:

NCT07311746

Conditions

T-cell Prolymphocytic Leukemia

Refractory T-Cell Prolymphocytic Leukemia

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Ruxolitinib

Cladribine

Venetoclax

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-08-25. This information was provided to ClinicalTrials.gov by M.D. Anderson Cancer Center on 2026-08-12.